Shares of Camurus (ST:CAMX) declined about 7% on Thursday following a regulatory decision by the U.S. Food and Drug Administration to reject the firm's application for Oclaiz, a therapy intended to treat acromegaly.
The FDA's response cites two specific actions: a request for reinspection of a third-party manufacturing facility and a request for a small change to the product labeling. The agency's decision did not flag concerns about clinical safety or efficacy.
Jefferies has outlined a potential timeline tied to the reinspection process. If the requested reinspection takes place in the second half of 2026, Jefferies expects that approval and a subsequent commercial launch would shift to the first half of 2027. That projected schedule depends directly on the timing of the FDA's facility reinspection.
Market commentary from Van Lanschot Kempen emphasized that, while the regulatory setback is negative in the short term, it does not alter the firm's assessment of Oclaiz's commercial potential. Van Lanschot Kempen estimates that Oclaiz accounts for roughly 9% of Camurus' current valuation.
Camurus' reported guidance remains intact for 2026; the FDA's rejection does not affect the company's outlook for that year. The agency's action appears targeted at manufacturing and labeling items rather than the underlying clinical profile of the medicine.
Acromegaly, the condition Oclaiz is designed to treat, is a hormonal disorder that leads to abnormal enlargement of bones, soft tissues, body parts and internal organs.
Contextual note: The FDA's request for reinspection of a manufacturing site and a small labeling change are the explicit reasons for the regulatory rejection as communicated; there is no indication in the agency's action that the drug's clinical safety or efficacy data were questioned.